Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab in MSI-H Solid Tumors with Persistent ctDNA
NCT03832569Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2019
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Proportion of patients with ctDNA clearance at 12 months. Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03832569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832569.